Tirzepatide
Mounjaro · Zepbound
A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
At a glance
- Category
- Metabolic
- Half-life
- ~5 days
- Typical vial sizes
- 5 mg · 10 mg · 20 mg · 30 mg
- Commonly cited dose
- 2500–15000 mcg
- Frequency
- once weekly
- Routes
- Subcutaneous
A 5 mg vial, worked through.
Reconstituting a 5 mg vial of Tirzepatide with 2 mL of bacteriostatic water gives 2.5 mg/mL. A 2500 mcg dose is then:
Storage
- Lyophilised (unmixed)
- Refrigerated.
- Reconstituted
- Refrigerate at 2–8°C. Follow compounding pharmacy guidance.
What people log it against
Outcomes users commonly track alongside this compound. Listing them is not a claim that it produces them.
- Weight management
- Glycaemic control
Read alongside Tirzepatide
Compounds this one is commonly compared with, combined with, or mistaken for. Listing a pairing is not a suggestion to run them together.
References
Each source below establishes only the specific claim noted with it, last checked 2026-08-13. Dose ranges, frequencies and storage times reflect what circulating protocols commonly state and are not established by these references.
- FDA label — MOUNJARO (tirzepatide), DailyMed
"an elimination half-life of approximately 5 days, enabling once-weekly dosing" — confirms halfLifeHours 120.
Run your own numbers
Pick Tirzepatide from the preset list to start from a typical vial.
As printed on the vial label
How much you inject into the vial
1000 mcg = 1 mg
Fills in a common vial size and the low end of commonly cited protocols. Always check against your own vial.
on a 1 mL U-100 insulin syringe
- Concentration
- 5 mg/mL
- Volume
- 0.05 mL
- Doses in this vial
- 40
Keep this vial. VialPal holds the concentration, counts down the doses left in it, and logs the ones you actually took.
VialPal does the arithmetic — it does not tell you what to take. Dose decisions belong between you and a qualified clinician.